Printer Friendly
The Free Library
14,678,741 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Research and Markets: Examine the Performance, Products, Pipeline and Potential of Merck & Co.


DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c69938) has announced the addition of "Merck & Co: Performance, Products, Pipeline and Potential" to their offering.

Pharmaceutical company intelligence reports from provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D.

An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Established in 1891, Merck & Co discovers, develops, manufactures and markets vaccines and pharmaceutical medicines to address unmet medical needs. The company operates on a global basis and is represented in more than 200 countries. Merck's headquarters are based in Whitehouse Station, NJ.

In December 2005, Merck announced a new research and development model designed to increase productivity and improve the probability of success by prioritising the company's R&D resources on nine priority disease areas: Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , atherosclerosis atherosclerosis (ăth'ərōsklərō`sĭs): see arteriosclerosis.
atherosclerosis
 or hardening of the arteries
, cardiovascular disease Cardiovascular disease
Disease that affects the heart and blood vessels.

Mentioned in: Lipoproteins Test

cardiovascular disease 
, diabetes, novel vaccines, obesity, oncology, pain and sleep disorders Sleep Disorders Definition

Sleep disorders are a group of syndromes characterized by disturbance in the patient's amount of sleep, quality or timing of sleep, or in behaviors or physiological conditions associated with sleep.
. Within these therapeutic areas, Merck will commit resources to achieve research breadth and depth, and to develop best-in-class targeted and differentiated products.

Merck will also make focused investments to pursue specific mechanisms in the following selected disease areas: antibiotics, antifungals, antivirals (hepatitis C Hepatitis C Definition

Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild.
 and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ), asthma, chronic obstructive pulmonary disease chronic obstructive pulmonary disease
n. Abbr. COPD
A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced.
, neurodegeneration, ophthalmology ophthalmology (ŏf'thălmŏl`əjē), branch of medicine specializing in the anatomy, function and diseases of the eye. Ophthalmologists specialize in the medical and surgical treatment of eye disorders, vision measurements for , osteoporosis, schizophrenia and stroke. In addition, the company will capitalise on selected opportunities outside these areas, by continuing to commercialise attractive clinical development candidates in the pipeline and by pursuing appropriate external licensing opportunities.

Merck plans to place more emphasis on active engagement with key opinion leaders to accelerate the development and diffusion of scientific information and devote additional resources to utilising technology and demonstrating product value to physicians. In the US, this approach has already resulted in productivity improvements in pilot programmes and is expected to lower Merck's spending per brand by 15 to 20 per cent by 2010.

In order to rejuvenate re·ju·ve·nate  
tr.v. re·ju·ve·nat·ed, re·ju·ve·nat·ing, re·ju·ve·nates
1. To restore to youthful vigor or appearance; make young again.

2.
 the company profile following the withdrawal of Vioxx, Merck has developed an impressive pipeline dominated by novel candidate compounds. Merck is also looking to expand therapeutic areas where it has experienced strong and recent success.

For more information, visit http://www.researchandmarkets.com/reports/c69938

Source: Espicom
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 28, 2007
Words:424
Previous Article:Osteologix to Present at NASDAQ MarketSite During EQUITIES 2007 Transatlantic Conference.(Conference news)
Next Article:ATEME to Showcase Latest H.264 Encoding Technology at Inter Airport 2007.
Topics:



Related Articles
Lane County's urban-forest fire risks rank high in study.(Fires)(A look at development in 11 states finds a potential for soaring firefighting costs)
Credibility, straight talk earn Motorola exec an EXCEL Award: IABC committee says Stu Reed seems to live and breathe communication.(inbox: IABC NEWS...
Delivering on the promise: financial results and membership growth highlight IABC's continued progress.(IABC 2006 ANNUAL REPORT)
Coaching for Emotional Intelligence.
Looking Forward: Your Performance Appraisal.
Care and Candor: Making Performance Appraisals Work.
Mold sealer eases release of low-VOC marine resins.(KEEPING UP WITH: Composites)
Kissei and Eisai Sign License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in China.
Eisai Announces Establishment of New Pharmaceutical Marketing Subsidiary in Belgium.
MHI Receives Order for Two Steam Turbine Generators for Sanmen Nuclear Power Plant in China.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles